BENEFITS 
The use of rhG-CSF and peripheral blood stem cells may shorten the amount of time needed to reach 
adequate blood counts, thereby potentially reducing the risk of infection and bleeding problems. 
ALTERNATIVES 
Alternative treatment includes an autologous marrow transplant without the use of rhG-CSF or 
peripheral blood stem cells. 
OTHER INFORMATION 
This treatment is being undertaken for the above described fatal disease. In agreeing to participate in a 
research program you are choosing to receive therapy that is not yet available outside of research 
institutions. This therapy is based on laboratory studies and/or exchange of information with other 
research centers. 
Your decision to participate in this study is voluntary and you may withdraw your consent at any time, 
for any reason, without notice and without prejudice. 
It is understood, that all medical expenses relating to,, or arising from, these procedures will be paid by 
you and/or your insurance company. The rhG-CSF will be provided free of charge by Amgen 
Corporation. Financial compensation is not available in the event of physical injury, adverse effects, or 
death resulting from this research project. 
Medical care will be authorized by the attending physician. You and/or your insurance company will be 
responsible for all costs arising from the medical care. 
In order to evaluate the results of this study, your medical records will need to be available to other 
physicians and researchers associated with the research project. The Food and Drug Administration 
Amgen Corporation and the National Institutes of Health will also have access to this information. All 
precautions to maintain confidentiality of medical records will be taken. Your personal identity will not 
be revealed in any publication or results. Study records will be maintained indefinitely for the purpose 
of analysis and follow-up. 
If you have questions about the research please contact your attending physician. If you have any 
questions about your rights as a research participant, please contact Karen Hansen in the Institutional 
Review Office of the Fred Hutchinson Cancer Research Center at 206/667-4867. 
Investigator Statement 
I have provided an explanation of the above -esearch program. The subject was given an opportunity to 
discuss the procedures, including possible alternatives, and to ask any additional questions. A signed 
copy of this consent form has been given to the subject. 
Investigator’s Signature 
/Date 
[356] 
Recombinant DNA Research, Volume 16 
